US Stock MarketDetailed Quotes

BTMD biote

Watchlist
  • 6.140
  • +0.080+1.32%
Close Nov 21 16:00 ET
200.78MMarket Cap20.47P/E (TTM)

biote Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

biote Q3 2024 Earnings Date

Currency：USDNov 12, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
51.38M
51.38M
0
+12.79%
+12.79%
0.00%
EPS
0.07
0.33
+0.26
Beat Est.
-72.00%
+37.50%
+371.43%
Analyst Rating
Strong Buy

Nov 13, 2024

biote Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 3 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 53.619M--
--2024/Q4-- / 51.294M--
Nov 12, 20242024/Q351.384M / 51.384M--
Aug 8, 20242024/Q249.169M / 49.062M--
May 7, 20242024/Q146.804M / 45.712M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 53.619M--
--2024/Q4-- / 51.294M--
Nov 12, 20242024/Q351.384M / 51.384M--
Aug 8, 20242024/Q249.169M / 49.062M--
May 7, 20242024/Q146.804M / 45.712M--

Unlock Free Earnings Estimates

biote Earnings Reports

  • 10-Q: Q3 2024 Earnings Report

    Nov 12 17:22 ET

  • 8-K: Biote Reports Third Quarter 2024 Financial Results Continued Profitable Growth Vertical integration drives gross profit margin improvement Launch of proprietary clinical decision support software to strengthen competitive advantages

    Nov 12 16:26 ET

  • 10-Q: Q2 2024 Earnings Report

    Aug 9 13:57 ET

  • 8-K: Biote Reports Second Quarter 2024 Financial Results Procedure revenue growth accelerates sequentially BioteRx roll-out on track with further expansion planned Management reiterates 2024 financial guidance

    Aug 8 16:48 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 13, 2024

    Strong Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg

    No Data